NOXXON Pharma N.V. (ALNOX.PA) Comparison with companies in other sectors?

NOXXON Pharma N.V. has a share price of N/A. You can analyze NOXXON Pharma N.V. (ALNOX.PA) competitors across different market sectors through stock heatmaps.

What are ALNOX.PA's NET and operating margins?

NOXXON Pharma N.V. (ALNOX.PA) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does ALNOX.PA's earnings per share (EPS) trend reflect its financial momentum?

NOXXON Pharma N.V. (ALNOX.PA) EPS is -0.22 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for NOXXON Pharma N.V. is -0.19, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for NOXXON Pharma N.V.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for NOXXON Pharma N.V. like P/E which is -0.00, P/B which is 0.003, and PEG which is -0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

NOXXON Pharma N.V.

ALNOX.PA•EURONEXT

Healthcare

Biotechnology

€0.04

€0.00(0.00%)

Fundamental Analysis of NOXXON Pharma N.V. (ALNOX.PA)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.22

P/E Ratio

-0.19

ROE

-2.36%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$0.00

Shares OutstandingTotal number of shares issued

Book Value/ShareNet worth per share

$14.33

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.219

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

-236.45%

ROAReturn on total assets

-147.96%

ROCEReturn on capital employed

-287.58%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-39.44

Cash/ShareCash and equivalents per share

$30.18

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ALNOX.PAFinancial Ratios Analysis details for ALNOX.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ALNOX.PASector Benchmarking details for ALNOX.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for NOXXON Pharma N.V. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of NOXXON Pharma N.V.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account NOXXON Pharma N.V.'s unique business strengths and challenges.

Key Financial Metrics for NOXXON Pharma N.V.

For NOXXON Pharma N.V., essential financial indicators include EPS -0.22, PE -0.19, and ROE -2.36. These key ratios reveal insights into NOXXON Pharma N.V.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare NOXXON Pharma N.V. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of NOXXON Pharma N.V.

Metrics like Net Margin - and ROA -147.96% shed light on how well NOXXON Pharma N.V. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether NOXXON Pharma N.V. can sustain its operations and continue growing in the future.

Valuation and Market Position of NOXXON Pharma N.V.

Using ratios such as P/B Ratio 0.003 and PEG Ratio -0.00, investors can assess whether NOXXON Pharma N.V. is appropriately valued based on its financials and growth potential. These figures, combined with NOXXON Pharma N.V.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for NOXXON Pharma N.V.

Financial health indicators, such as Debt/Equity Ratio 0.54 and Cash Flow $-39.44, provide a snapshot of NOXXON Pharma N.V.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like NOXXON Pharma N.V., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for NOXXON Pharma N.V.

Investing in NOXXON Pharma N.V. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at NOXXON Pharma N.V. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;